The first longevity drug may be for dogs. That's the honest path, and here's why.

Loyal, the company developing lifespan-extension drugs for dogs, announced a $100 million Series C today, bringing its total raised past $250 million. Its lead product, LOY-002, is a daily beef-flavored pill for senior dogs that targets metabolic drivers of aging. The company has completed two of the three requirements for an FDA conditional approval for animal drugs — a "reasonable expectation of effectiveness" and target-animal safety — with manufacturing the remaining piece, and plans to submit later this year. Its pivotal trial, STAY, enrolled about 1,300 dogs at some seventy veterinary clinics, which the company calls the largest in veterinary history. The expected label is dogs at least ten years old and fourteen pounds; the expected price, by the company's optimistic projection, is under $100 a month. We think this is the most honest project in the longevity industry, and we want to explain why a dog pill earns that word when so much sold to humans does not.

Why dogs are the right experiment. A lifespan trial in people takes decades and nobody runs one, which is why human longevity products rest on biomarkers and mice. A dog lives ten to fourteen years, ages in the same house as its owner, and gets veterinary care, so a trial can actually measure the thing claimed: did treated dogs live longer and better? That is what STAY is designed to do, under a regulator, with a defined label. The caveats are the usual ones — the trial's results are not public, "reasonable expectation" is a regulatory threshold rather than proof, and a conditional approval is conditional. But the structure is correct: a specific claim, a controlled trial, an outcome that matters, a referee.

Ben’s take

Compare the two business models. The human longevity aisle sells the promise of a longer life with no trial, to the customer directly, forever. Loyal is spending $250 million to earn the right to make one claim about one species, and it will have to show a regulator evidence before it ships a pill. If the drug works, the owner buys it for a dog that is demonstrably living longer; if it does not, the label never issues. That is what accountability looks like, and it is why I would rather see capital here than in another biomarker panel.

Loree’s take

Patients will ask me whether a dog's longevity drug means a human one is close. It does not. What it means is that someone is finally running the experiment the human industry skips — and that the honest answer about any aging drug is the one Loyal's trial will give for dogs: we will know when the animals that took it have lived their lives. Until then, for both species, the evidence-based prescription is the same. Walk the dog.

Why it matters to a recovering optimizer. The lesson is not about pets. It is that the question "does this extend life?" can be answered properly only by a trial that waits for lives to end, and that the only part of the longevity industry willing to wait is working on an animal whose life is short enough to watch. Everything sold to you as a longevity intervention this year is a claim that has not been — and mostly cannot be — tested that way. The dog gets a real trial. You get a testimonial.